Results-Vaccine coverage for hepatitis B dropped sharply from 99% to 53% to 39% for the first, second, and third doses respectively. In contrast, vaccine coverage was maintained at 97-99% for the three doses of poliomyelitis vaccine. Serological evaluation of vaccine efficacy showed that only 3-5% of recipients of all three doses failed to develop antibodies to hepatitis B surface antigen. Only 6-6% of vaccine recipients were vaccinated according to either the early or later schedules whereas 93 4% received their doses of vaccine at intervals beyond the limits of either of the planned schedules. There was, however, no significant difference in seroconversion to the surface antigen between the "unscheduled" or scheduled groups or those who were vaccinated according to the early or late schedules. The pattern of prevalence of antibodies to hepatitis B core antigen, which showed a sharp fail in children aged over 7 months, suggested that the antibodies were acquired passively rather than by active infection.
During 1989 a year long campaign supplementing the routine expanded programme on immunisation with hepatitis B vaccine was carried out in the Republic of Venda, a self governing region of some 7460 square kilometres in the far north of South Africa. With a population of some 500 000 at a density of 69 people per square kilometre, Venda consists almost entirely of black communities living in conditions varying from rural agricultural settlements to small towns. As in other rural African communities hepatitis B endemicity is high, and a 1986 study of 29 312 adult black male mineworkers of rural origin from throughout southern Africa found that the hepatitis B surface antigen carrier rate ranged from 5 5% to 14-0%, with that from Venda being 8 in 683 there was also sufficient serum for testing for antibodies to core antigen, but there was insufficient serum in most specimens for any additional tests. All blood specimens, both antenatally from the mothers and from the infants, were taken only after obtaining informed consent from the mothers. The study was approved by the human ethics committee of the University of Witwatersrand.
SEROLOGY
All hepatitis B virus markers were tested by radioimmunoassay (Abbott Laboratories, Chicago, Illinois), and antibodies to hepatitis B surface antigen were measured in mIU/ml using the WHO reference preparation as a standard. A positive titre was defined as having >10 mIU of antibodies. Data were analysed statistically using either a X' test or Fisher's exact test.
Results
In the study of mothers attending antenatal clinics, 3S5% In three newborn babies a self limiting osteomyelitis of the femur developed after inoculation, and two minor injection abscesses were also seen after the first injection. No other side effects from the vaccine were reported.
Discussion
Sub-Saharan Africa is a vast reservoir of hepatitis B virus infection, and routine immunisation programmes need to be implemented urgently. With the present state of primary health care programmes in most of the continent, however, adding another vaccine to prevent a disease that is largely invisible during infancy and childhood requires considerable planning to devise effective strategies. Three major difficulties need to be considered before hepatitis B vaccine can be incorporated as a seventh vaccine in the expanded programme on immunisation in rural Africa. Firstly, the cost of the vaccine must be reduced, and vaccine manufacturers and perhaps also sponsoring bodies must strive to bring the cost below $1 per dose to these countries.' The second and third fundamental difficulties relate to the need for wide flexibility of dosage schedules and also the means of ensuring maintenance of satisfactory coverage for the second and third doses.
In the initial evaluations of the efficacy of hepatitis B vaccine in neonates and infants between 1981 and 1985 seroconversion rates varying from 64% to 100% were achieved. 2 In most of these trials vaccine schedules of 0, 1, and 6 months or 0, 1, and 2 months were used to conform to the dosage schedules recommended for adult immunisation and to administer the first dose as soon as possible after birth to interrupt perinatal transmission of hepatitis B virus. Adding an extra vaccine to the present six in the expanded programme on immunisation would, however, necessitate integration in ways that strengthen existing programmes, and therefore timing of vaccine doses would need to comply with existing schedules.
Administration of hepatitis B vaccine at 0, 2, 4, and 9 months in The Gambia9 and three injections at monthly intervals with a booster a year later in Senegal,8 were highly effective in short term and long term seroresponses. Nevertheless, two major difficulties remain in regard to field conditions in rural African communities. Firstly, there is a difficulty in complying with WHO recommendations for the first dose to be given as soon as possible after birth because most births do not take place in hospital or clinics and access for the neonatal dose is difficult. Secondly, administration of all three doses within reasonable limits of the recommended vaccine schedules is often difficult to implement in rural African conditions, where distances to clinics are often great and mobile outreach clinics are impeded by poor road conditions. Indeed, in our study 93-4% of the infants evaluated serologically fell into the "unscheduled" group who received their three doses of vaccine at widely varying times. However, unlike the Far East where perinatal transmission plays a key part in maintaining carriage of chronic hepatitis B virus,5 in southern Africa horizontal transmission later in infancy is of greater importance than perinatal spread. Thus in rural Kangwane in the eastern Transvaal perinatal infection was found to be uncommon,'3 and in Namibia most carriers had been infected after the age of 11 Evaluation of the sample of 863 fully immunised infants showed that 96 5% were positive for antibodies to hepatitis B surface antigen. No significant differences in seroresponse rates were observed between those receiving vaccine in the early or later schedules, whether a defined schedule was followed or vaccine doses were given at widely variable intervals, or whether vaccine was administered by fixed clinics or by mobile GOBI teams. Unfortunately, few capillary specimens were available with sufficient serum to test for surface antigen to assess protection, but tests for antibodies to core antigen could be carried out on 683 of the 863 specimens and the distribution of the 28 positive results, occurring predominantly in infants aged 7 months or less and declining sharply thereafter, is consistent with passively acquired maternal antibodies rather than with active infection. The low prevalence of antibodies to core antigen could also be explained by infection with the variant of hepatitis B virus 2 described in Senegal'6 which produces a positive result for surface antigen but a negative result for core antigen, although these variants have not yet been observed in this part of Africa. Botha et al similarly found passively acquired maternal antibodies persisting up to the age of 7-12 months. '4 Integration of hepatitis B vaccine into routine immunisation programmes can thus be highly effective in rural Africa even within wide limits of dosage schedules. Starting immunisation could also be delayed by two or three months to fit in with the expanded programme on immunisation wherever there would be difficulties in administering the neonatal dose.
Of great concern was the high dropout rate after the first dose. The health region had had excellent vaccine coverage on previous WHO cluster surveys and during the term of this study maintained coverage for polio 1, 2, and 3 (and presumably also for diphtheria, tetanus, and pertussis 1, 2, and 3) at 97-99%. Acceptance and awareness after extensive educational and publicity efforts throughout the region was particularly high, and this was borne out by the 99% coverage for the first dose. Yet in spite of this there was obviously a breakdown in complete implementation of the vaccination programme at the periphery after the first dose of hepatitis B vaccine had been administered. There were a number of possible reasons for this. Firstly, the novel hepatitis B vaccine was introduced and distributed differently from the vaccines in the expanded programme on immunisation with which primary health care workers were familiar, resulting in recurring shortages at vaccination points. Thus, although infants would be present at scheduled times, coverage for hepatitis B was handicapped by the need for an additional catch up visit. This was further compromised by mobile clinic visits being spaced at six week intervals. Confusion also arose with regard to whether infants fell into the planned early or late schedule group when the first dose had been delayed for a few weeks, and this occasionally resulted in failure to complete either schedule. In some cases health care workers and mothers complained about the extra injection for hepatitis, and mothers were also requested to BMJ VOLUME 302 
Abstract
Objective-To establish whether there is evidence of the efficacy of homoeopathy from controlled trials in humans.
Design-Criteria based meta-analysis. Assessment of the methodological quality of 107 controlled trials in 96 published reports found after an extensive search. Trials were scored using a list of predefined criteria of good methodology, and the outcome of the trials was interpreted in relation to their quality.
Setting-Controlled trials published world wide. Main outcome measures-Results of the trials with the best methodological quality. Trials of classical homoeopathy and several modern varieties were considered separately.
Results-In 14 trials some form of classical homoeopathy was tested and in 58 trials the same single homoeopathic treatment was given to patients with comparable conventional diagnoses. Combinations of several homoeopathic treatments were tested in 26 trials; isopathy was tested in nine trials. Most trials seemed to be of very low quality, but there were many exceptions. The results showed a positive trend regardless of the quality of the trial or the variety of homoeopathy used. Overall, of the 105 trials with interpretable results, 81 trials indicated positive results whereas in 24 trials no positive effects of homoeopathy were found. The results of the review may be complicated by publication bias, especially in such a controversial subject as homoeopathy.
Conclusions-At the moment the evidence of clinical trials is positive but not sufficient to draw definitive conclusions because most trials are of low methodological quality and because of the unknown role of publication bias. This indicates that there is a legitimate case for further evaluation of homoeopathy, but only by means of well performed trials.
Introduction
A survey of 293 general practitioners in The Netherlands showed that 45% of them think that homoeopathic remedies are efficacious in treating upper respiratory tract infections or hay fever.' On the other hand, many doctors do not believe that homoeopathy is an efficacious treatment as it is highly implausible that infinitesimally diluted substances retain their biological effects. It is also often stated that homoeopathy has not been evaluated using modern methods -that is, controlled trials. The first argument may be true, but the second is certainly not true. Reading an article about pollen C30 in hay fever increased our interest in homoeopathy.2 We could not believe the positive result (was it coincidence?) and therefore we started to search for further reports. Here we present 107 controlled trials of homoeopathy.
Homoeopathic medicine is a system developed by Samuel Hahnemann from the similia concept: "similia similibus curantur." This implies that a diluted, "potentised" agent, which (when undiluted) in healthy
